Citizens Jmp Boosts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $8.00

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price upped by Citizens Jmp from $5.00 to $8.00 in a report released on Friday,Benzinga reports. The firm currently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price target would indicate a potential upside of 31.04% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the company. Chardan Capital reduced their price target on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Barclays reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Iovance Biotherapeutics in a research report on Friday. Robert W. Baird set a $6.00 price objective on shares of Iovance Biotherapeutics in a report on Friday. Citigroup reaffirmed an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Iovance Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $8.75.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA traded down $0.10 during trading hours on Friday, hitting $6.11. The company had a trading volume of 12,291,391 shares, compared to its average volume of 15,458,137. The stock has a 50-day moving average price of $4.35 and a 200 day moving average price of $3.78. The company has a market capitalization of $2.73 billion, a PE ratio of -6.48 and a beta of 0.71. Iovance Biotherapeutics has a 52 week low of $1.76 and a 52 week high of $6.92.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The company had revenue of $198.63 million for the quarter, compared to analysts’ expectations of $87.83 million. During the same quarter in the previous year, the company earned ($0.33) earnings per share. Iovance Biotherapeutics’s quarterly revenue was up 65.7% on a year-over-year basis. Analysts anticipate that Iovance Biotherapeutics will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in IOVA. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at about $269,000. First National Bank & Trust Co. of Newtown purchased a new stake in shares of Iovance Biotherapeutics during the 2nd quarter worth $51,000. Flputnam Investment Management Co. purchased a new position in Iovance Biotherapeutics in the second quarter worth $108,000. Bank of New York Mellon Corp acquired a new position in shares of Iovance Biotherapeutics during the second quarter valued at about $4,834,000. Finally, GSA Capital Partners LLP purchased a new stake in Iovance Biotherapeutics during the 2nd quarter valued at about $2,726,000. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Record revenue and earnings beat: Iovance reported approximately $99.3 million in second-quarter revenue, up 66% year over year and 39% from the prior quarter. The $0.11 per-share loss was narrower than the $0.13 consensus estimate and substantially improved from a $0.33 loss a year earlier. Iovance second-quarter results
• Positive Sentiment: Amtagvi demand is driving growth: U.S. Amtagvi revenue reached roughly $91 million, while the authorized treatment-center network surpassed 95 locations and is expected to exceed 110 by year-end. Gross margin also improved to 56% as manufacturing efficiencies and cost controls took effect. Amtagvi powers second-quarter beat
• Positive Sentiment: Pipeline and regulatory catalysts expanded: The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also anticipating clinical updates in non-small-cell lung cancer and melanoma at upcoming medical conferences, potentially supporting larger future markets. Iovance pipeline update
• Neutral Sentiment: Buyout speculation and options activity: Media reports cited increasing acquisition speculation, while call-option volume was approximately 64% above average. Neither indicates a confirmed transaction, so these developments may amplify volatility without changing Iovance’s fundamentals. IOVA buyout speculation
• Negative Sentiment: Profitability remains a risk: Iovance still posted a $47.3 million net loss and continues to carry substantial research and development expenses. Management is reviewing its $350 million–$370 million 2026 revenue outlook rather than raising it immediately, leaving some uncertainty around the pace of growth and the path to profitability.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.